The place of PD-1 inhibitors in melanoma management

Affiliations

¹ Rockingham General Hospital, Cooloongup, WA, Australia.
² Christie NHS Foundation Trust and University of Manchester, Manchester, M20 4BX, UK. Electronic address: paul.lorigan@christie.nhs.uk.

Comment

Samantha Bowyer et al. Lancet Oncol. 2015 Aug.

. 2015 Aug;16(8):873-4.

doi: 10.1016/S1470-2045(15)00094-7. Epub 2015 Jun 23.

¹ Rockingham General Hospital, Cooloongup, WA, Australia.
² Christie NHS Foundation Trust and University of Manchester, Manchester, M20 4BX, UK. Electronic address: paul.lorigan@christie.nhs.uk.

No abstract available

Comment on

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.
Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, Hodi FS, Schachter J, Pavlick AC, Lewis KD, Cranmer LD, Blank CU, O'Day SJ, Ascierto PA, Salama AK, Margolin KA, Loquai C, Eigentler TK, Gangadhar TC, Carlino MS, Agarwala SS, Moschos SJ, Sosman JA, Goldinger SM, Shapira-Frommer R, Gonzalez R, Kirkwood JM, Wolchok JD, Eggermont A, Li XN, Zhou W, Zernhelt AM, Lis J, Ebbinghaus S, Kang SP, Daud A. Ribas A, et al. Lancet Oncol. 2015 Aug;16(8):908-18. doi: 10.1016/S1470-2045(15)00083-2. Epub 2015 Jun 23. Lancet Oncol. 2015. PMID: 26115796 Free PMC article. Clinical Trial.